Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220737 · ClinicalTrials.gov registry record · Phase 4
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
A Phase 4 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 4
- Development phase
- 550
- Enrollment target
NCT03220737 is a Phase 4 study that has completed, run by Bavarian Nordic. The registered enrollment target is 550 participants.
The verdict
NCT03220737, a Phase 4 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 550 participants
- Enrollment target
Study Summary
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18 through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase 4 study are to evaluate the safety and immunogenicity of a single dose of VAXCHORA (1 x 10e9 cfu/dose) in children ages 2 years to \<18 years of age in developed countries.
Interventions
- OTHER Placebo
- BIOLOGICAL VAXCHORA (Cholera Vaccine, Live, Oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220737
The ClinicalTrials.gov registry entry for NCT03220737 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03220737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220737 about?
NCT03220737 is a clinical study titled "VAXCHORA Pediatric Study to Assess Safety and Immunogenicity". VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in adults 18 through 64 years of age travelling to cholera-affected areas. The primary goals of this Phase 4 study are to evaluat...
What is the current status of trial NCT03220737?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 550 participants. The study started on 2017-07-21. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT03220737?
The interventions under investigation include: Placebo (OTHER), VAXCHORA (Cholera Vaccine, Live, Oral) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03220737?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.